Genprex, Inc. operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells. Genprex, Inc. was founded in 2009 and is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable
Genprex (NASDAQ:GNPX) Frequently Asked Questions
What is Genprex's stock symbol?
Genprex trades on the NASDAQ under the ticker symbol "GNPX."
How were Genprex's earnings last quarter?
Genprex Inc (NASDAQ:GNPX) released its quarterly earnings data on Monday, April, 1st. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.10. View Genprex's Earnings History.
When is Genprex's next earnings date?
What price target have analysts set for GNPX?
2 Wall Street analysts have issued 12 month price targets for Genprex's stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Genprex's share price to reach $5.00 in the next year. This suggests a possible upside of 16.8% from the stock's current price. View Analyst Price Targets for Genprex.
What is the consensus analysts' recommendation for Genprex?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genprex.
Has Genprex been receiving favorable news coverage?
Press coverage about GNPX stock has been trending extremely negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Genprex earned a coverage optimism score of -5.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Genprex.
Are investors shorting Genprex?
Genprex saw a increase in short interest in January. As of January 31st, there was short interest totalling 697,600 shares, an increase of 79.1% from the January 15th total of 389,600 shares. Based on an average trading volume of 2,660,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 5.3% of the shares of the stock are short sold. View Genprex's Current Options Chain.
What other stocks do shareholders of Genprex own?
Who are Genprex's key executives?
Genprex's management team includes the folowing people:
- Mr. John Rodney Varner, Co-Founder, CEO, Sec. & Chairman (Age 62)
- Dr. Julien L. Pham M.P.H., M.D., MPH, Pres & COO (Age 42)
- Mr. Ryan M. Confer, Chief Financial Officer (Age 37)
- Dr. Jack A. Roth FACS, M.D., Chairman of Scientific & Medical Advisory Board
Who are Genprex's major shareholders?
Genprex's stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.72%). Company insiders that own Genprex stock include Jack A Roth, John Rodney Varner and Julien L Pham. View Institutional Ownership Trends for Genprex.
Which institutional investors are buying Genprex stock?
GNPX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Genprex stock in the last two years include Jack A Roth, John Rodney Varner and Julien L Pham. View Insider Buying and Selling for Genprex.
How do I buy shares of Genprex?
Shares of GNPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Genprex's stock price today?
One share of GNPX stock can currently be purchased for approximately $4.28.
MarketBeat Community Rating for Genprex (NASDAQ GNPX)
MarketBeat's community ratings are surveys of what our community members think about Genprex and other stocks. Vote "Outperform" if you believe GNPX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNPX will underperform the S&P 500 over the long term. You may vote once every thirty days.
